Short Circuiting
Cancer's Chaos
WHO WE ARE
Volastra is a patient-focused clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer medicines that target the biology of chromosomal instability.
MORE ABOUT US
WHY CIN?
Chromosomal instability, or CIN, is a hallmark of cancer which is found in 60-80% of all tumors. It is associated with aggressive disease and poor survival.
OUR SCIENCE
IN THE CLINIC
Our two differentiated lead clinical programs each target KIF18A, a protein which plays an essential role in the successful division of cancer cells.
OUR PIPELINE
OUR RECENT PRESS RELEASES
VIEW ALL PRESS RELEASES
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]
Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline
Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will support clinical development of Volastra’s […]
A closer look at Volastra’s lead program: KIF18A inhibitor
By Christina Eng, Ph.D., VP, Head of Biology Earlier this month at the FASEB Consequences of Aneuploidy conference, we shared […]